As the biosimilar sector matures, what are the key issues that are shaping commercial strategies? As physician and payer confidence in the use of biosimilars grows, US and European companies are having to rethink their...

Are you employing the latest technology and techniques to power your patient journey mapping? "Pharma companies first need to understand that their task is not to produce new product; their task is to provide a really...

As digital health progressively enters mainstream therapy, how should it be regulated and to what outcome? Digital health is booming and as investment in digital health technology grows more products and services will...

Are you ready for fundamental disruption to key account management practice? While the Key Account Management (KAM) role will continue to prioritise the development of long-term, sustainable partnerships between...

What factors determine a Key Account Manager (KAM) team's size and structure? At what stage in a product's lifecycle are KAMs assigned and how many brands should a typical KAM support? What personal attributes and...

Are you fully and efficiently exploiting real-world data across your business? The impact of real-world data (RWD) is growing but few companies are fully exploiting its potential across all clinical and commercial areas...

As the European biosimilars market surges, what do payers see as the next steps? The approval in 2018 of biosimilar versions of adalimumab (Abbvie's Humira) and trastuzumab (Roche's Herceptin) is a major boost to the...

Understand which MSL activities are seen as being most important in the US and Western Europe Benchmark your own MSL programmes and identify new ways to improve performance Identify the most widely-used performance...